Mechanistic link between nonalcoholic fatty liver disease and cardiometabolic disorders

International Journal of Cardiology

Volumn 201, Issue , 2015, Pages 408-414

  Lim, Soo ^a   Oh, Tae Jung ^a   Koh, Kwang Kon ^b  

^a Seoul National University Bundang Hospital   (South Korea)

^b Gachon University College of Medicine   (South Korea)

Author keywords

Atherosclerosis; Cardiovascular disease; Gut microbiota; Inflammation; Insulin resistance; Non alcoholic fatty liver disease; Oxidative stress

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; ASCORBIC ACID; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; FATTY ACID; GAMMA GLUTAMYLTRANSFERASE; METFORMIN; PIOGLITAZONE; PITAVASTATIN; PREBIOTIC AGENT; PROBIOTIC AGENT; REACTIVE OXYGEN METABOLITE; SIMVASTATIN; VERY LOW DENSITY LIPOPROTEIN; BIOLOGICAL MARKER;

ARTICLE; ATHEROSCLEROSIS; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; DISEASE ASSOCIATION; DYSBIOSIS; DYSLIPIDEMIA; FATTY LIVER; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INTESTINE FLORA; LIFESTYLE MODIFICATION; LIVER FIBROSIS; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; ANIMAL; COMPLICATION; METABOLISM; RISK FACTOR;

ANIMALS; BIOMARKERS; CARDIOVASCULAR DISEASES; HUMANS; NON-ALCOHOLIC FATTY LIVER DISEASE; RISK FACTORS;

EID: 84943540060     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.08.107     Document Type: Review

References (101)

1. E. Fabbrini, S. Sullivan, and S. Klein Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications Hepatology 51 2010 679 689
2. N. Stefan, and H.U. Haring The metabolically benign and malignant fatty liver Diabetes 60 2011 2011 2017
3. J.C. Cohen, J.D. Horton, and H.H. Hobbs Human fatty liver disease: old questions and new insights Science 332 2011 1519 1523
4. A. Marcos, R.A. Fisher, J.M. Ham, and et al. Selection and outcome of living donors for adult to adult right lobe transplantation Transplantation 69 2000 2410 2415
5. C.D. Zois, G.H. Baltayiannis, A. Bekiari, and et al. Steatosis and steatohepatitis in postmortem material from Northwestern Greece World J. Gastroenterol. 16 2010 3944 3949
6. A. Amarapurkar, and T. Ghansar Fatty liver: experience from western India Ann. Hepatol. 6 2007 37 40
7. J.Y. Lee, K.M. Kim, S.G. Lee, and et al. Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center J. Hepatol. 47 2007 239 244
8. R.M. Williamson, J.F. Price, S. Glancy, and et al. Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study Diabetes Care 34 2011 1139 1144
9. F.S. Wang, J.G. Fan, Z. Zhang, and et al. The global burden of liver disease: the major impact of China Hepatology 60 2014 2099 2108
10. N.H. Kim, J. Park, S.H. Kim, and et al. Non-alcoholic fatty liver disease, metabolic syndrome and subclinical cardiovascular changes in the general population Heart 100 2014 938 943
11. R. Loomba, and A.J. Sanyal The global NAFLD epidemic Nat. Rev. Gastroenterol. Hepatol. 10 2013 686 690
12. P. Angulo Nonalcoholic fatty liver disease N. Engl. J. Med. 346 2002 1221 1231
13. M. Ekstedt, L.E. Franzen, U.L. Mathiesen, and et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes Hepatology 44 2006 865 873
14. M. Stepanova, and Z.M. Younossi Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population Clin. Gastroenterol. Hepatol. 10 2012 646 650
15. A.L. Birkenfeld, and G.I. Shulman Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes Hepatology 59 2014 713 723
16. C.D. Byrne, and G. Targher Ectopic fat, insulin resistance, and nonalcoholic fatty liver disease: implications for cardiovascular disease Arterioscler. Thromb. Vasc. Biol. 34 2014 1155 1161
17. H. Tilg, and A.R. Moschen Insulin resistance, inflammation, and non-alcoholic fatty liver disease Trends Endocrinol. Metab. 19 2008 371 379
18. R.M. Al, M.G. Silverman, K. Nasir, and et al. The association of nonalcoholic fatty liver disease, obesity, and metabolic syndrome, with systemic inflammation and subclinical atherosclerosis: The Multi-Ethnic Study of Atherosclerosis (MESA) Atherosclerosis 239 2015 629 633
19. B. Schnabl, and D.A. Brenner Interactions between the intestinal microbiome and liver diseases Gastroenterology 146 2014 1513 1524
20. E.K. Speliotes, J.M. Massaro, U. Hoffmann, and et al. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study Hepatology 51 2010 1979 1987
21. N.M. de Alwis, and C.P. Day Non-alcoholic fatty liver disease: the mist gradually clears J. Hepatol. 48 Suppl. 1 2008 S104 S112
22. N. Rafiq, C. Bai, Y. Fang, and et al. Long-term follow-up of patients with nonalcoholic fatty liver Clin. Gastroenterol. Hepatol. 7 2009 234 238
23. E. Fabbrini, F. Magkos, B.S. Mohammed, and et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity Proc. Natl. Acad. Sci. U. S. A. 106 2009 15430 15435
24. L.B. VanWagner, J.E. Wilcox, L.A. Colangelo, and et al. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: a population-based study Hepatology 62 2015 773 783
25. N. Li, G.W. Zhang, J.R. Zhang, and et al. Non-alcoholic fatty liver disease is associated with progression of arterial stiffness Nutr. Metab. Cardiovasc. Dis. 25 2015 218 223
26. G. Targher, L. Bertolini, S. Rodella, and et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients Diabetes Care 30 2007 2119 2121
27. M. Hamaguchi, T. Kojima, N. Takeda, and et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease World J. Gastroenterol. 13 2007 1579 1584
28. C.A. Matteoni, Z.M. Younossi, T. Gramlich, and et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity Gastroenterology 116 1999 1413 1419
29. N. Sattar, O. Scherbakova, I. Ford, and et al. Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study Diabetes 53 2004 2855 2860
30. A.J. Hanley, K. Williams, A. Festa, and et al. Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study Diabetes 54 2005 3140 3147
31. N.H. Cho, H.C. Jang, S.H. Choi, and et al. Abnormal liver function test predicts type 2 diabetes: a community-based prospective study Diabetes Care 30 2007 2566 2568
32. N. Nakanishi, K. Suzuki, and K. Tatara Serum gamma-glutamyltransferase and risk of metabolic syndrome and type 2 diabetes in middle-aged Japanese men Diabetes Care 27 2004 1427 1432
33. M. Maximos, F. Bril, S.P. Portillo, and et al. The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease Hepatology 61 2015 153 160
34. P. Portillo-Sanchez, F. Bril, M. Maximos, and et al. High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels J. Clin. Endocrinol. Metab. 100 2015 2231 2238
35. M.M. Severova, E.A. Saginova, M.G. Galliamov, and et al. Clinicopathogenetic characteristics of cardiorenal syndrome in non-alcoholic fatty liver disease Ter. Arkh. 84 2012 15 20
36. H. Hashizume, K. Sato, Y. Yamazaki, and et al. A prospective study of long-term outcomes in female patients with nonalcoholic steatohepatitis using age- and body mass index-matched cohorts Acta Med. Okayama 67 2013 45 53
37. G. Marchesini, M. Brizi, G. Bianchi, and et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome Diabetes 50 2001 1844 1850
38. G. Bhat, C.S. Baba, A. Pandey, and et al. Life style modification improves insulin resistance and liver histology in patients with non-alcoholic fatty liver disease World J. Hepatol. 4 2012 209 217
39. W.L. Chen, H.W. Wei, W.Z. Chiu, and et al. Metformin regulates hepatic lipid metabolism through activating AMP-activated protein kinase and inducing ATGL in laying hens Eur. J. Pharmacol. 671 2011 107 112
40. Y.M. Song, Y.H. Lee, J.W. Kim, and et al. Metformin alleviates hepatosteatosis by restoring SIRT1-mediated autophagy induction via an AMP-activated protein kinase-independent pathway Autophagy 11 2015 46 59
41. W.W. Shields, K.E. Thompson, G.A. Grice, and et al. The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot trial Ther. Adv. Gastroenterol. 2 2009 157 163
42. J.W. Haukeland, Z. Konopski, H.B. Eggesbo, and et al. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial Scand. J. Gastroenterol. 44 2009 853 860
43. A.J. Sanyal, N. Chalasani, K.V. Kowdley, and et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis N. Engl. J. Med. 362 2010 1675 1685
44. G. Gentric, V. Maillet, V. Paradis, and et al. Oxidative stress promotes pathologic polyploidization in nonalcoholic fatty liver disease J. Clin. Invest. 125 2015 981 992
45. R. Gambino, G. Musso, and M. Cassader Redox balance in the pathogenesis of nonalcoholic fatty liver disease: mechanisms and therapeutic opportunities Antioxid. Redox Signal. 15 2011 1325 1365
46. M. Cassader, R. Gambino, G. Musso, and et al. Postprandial triglyceride-rich lipoprotein metabolism and insulin sensitivity in nonalcoholic steatohepatitis patients Lipids 36 2001 1117 1124
47. L.S. Bhatia, N.P. Curzen, and C.D. Byrne Nonalcoholic fatty liver disease and vascular risk Curr. Opin. Cardiol. 27 2012 420 428
48. N.V. Leach, E. Dronca, S.C. Vesa, and et al. Serum homocysteine levels, oxidative stress and cardiovascular risk in non-alcoholic steatohepatitis Eur. J. Intern. Med. 25 2014 762 767
49. G.S. Hotamisligil Inflammatory pathways and insulin action Int. J. Obes. Relat. Metab. Disord. 27 Suppl. 3 2003 S53 S55
50. H. Hyogo, S. Yamagishi, K. Iwamoto, and et al. Elevated levels of serum advanced glycation endproducts in patients with non-alcoholic steatohepatitis J. Gastroenterol. Hepatol. 22 2007 1112 1119
51. K. Iwamoto, K. Kanno, H. Hyogo, and et al. Advanced glycation end products enhance the proliferation and activation of hepatic stellate cells J. Gastroenterol. 43 2008 298 304
52. N. Tahara, S. Yamagishi, M. Takeuchi, and et al. Positive association between serum level of glyceraldehyde-derived advanced glycation end products and vascular inflammation evaluated by [(18)F]fluorodeoxyglucose positron emission tomography Diabetes Care 35 2012 2618 2625
53. T. Foster, M.J. Budoff, S. Saab, and et al. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial Am. J. Gastroenterol. 106 2011 71 77
54. S. Lim, J.P. Despres, and K.K. Koh Prevention of atherosclerosis in overweight/obese patients. - in need of novel multi-targeted approaches Circ. J. 75 2011 1019 1027
55. G. Targher, C.P. Day, and E. Bonora Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease N. Engl. J. Med. 363 2010 1341 1350
56. N. Stefan, K. Kantartzis, and H.U. Haring Causes and metabolic consequences of fatty liver Endocr. Rev. 29 2008 939 960
57. S.E. Shoelson, J. Lee, and A.B. Goldfine Inflammation and insulin resistance J. Clin. Invest. 116 2006 1793 1801
58. C.J. Lavie, R.V. Milani, A. Verma, and et al. C-reactive protein and cardiovascular diseases - is it ready for primetime? Am. J. Med. Sci. 338 2009 486 492
59. J.K. Dowman, J.W. Tomlinson, and P.N. Newsome Pathogenesis of non-alcoholic fatty liver disease QJM 103 2010 71 83
60. Y.S. Hamirani, R. Katz, K. Nasir, and et al. Association between inflammatory markers and liver fat: the multi-ethnic study of atherosclerosis J. Clin. Exp. Cardiol. 5 2014
61. J. Yamada, H. Tomiyama, M. Yambe, and et al. Elevated serum levels of alanine aminotransferase and gamma glutamyltransferase are markers of inflammation and oxidative stress independent of the metabolic syndrome Atherosclerosis 189 2006 198 205
62. C. Herder, M. Peltonen, W. Koenig, and et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish diabetes prevention study Diabetes 55 2006 2340 2346
63. S. Kiechl, E. Lorenz, M. Reindl, and et al. Toll-like receptor 4 polymorphisms and atherogenesis N. Engl. J. Med. 347 2002 185 192
64. I. Jialal, H. Kaur, and S. Devaraj Toll-like receptor status in obesity and metabolic syndrome: a translational perspective J. Clin. Endocrinol. Metab. 99 2014 39 48
65. B. Vozarova, N. Stefan, R.S. Lindsay, and et al. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes Diabetes 51 2002 1889 1895
66. R. Belfort, S.A. Harrison, K. Brown, and et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis N. Engl. J. Med. 355 2006 2297 2307
67. W. Wang, C. Zhao, J. Zhou, and et al. Simvastatin ameliorates liver fibrosis via mediating nitric oxide synthase in rats with non-alcoholic steatohepatitis-related liver fibrosis PLoS One 8 2013 e76538
68. M. Ekstedt, L.E. Franzen, U.L. Mathiesen, and et al. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study J. Hepatol. 47 2007 135 141
69. H. Hyogo, T. Ikegami, K. Tokushige, and et al. Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: an open-label, pilot study Hepatol. Res. 41 2011 1057 1065
70. T.W. Jung, B.S. Youn, H.Y. Choi, and et al. Salsalate and adiponectin ameliorate hepatic steatosis by inhibition of the hepatokine fetuin-A Biochem. Pharmacol. 86 2013 960 969
71. J.M. Sabate, P. Jouet, F. Harnois, and et al. High prevalence of small intestinal bacterial overgrowth in patients with morbid obesity: a contributor to severe hepatic steatosis Obes. Surg. 18 2008 371 377
72. A.J. Wigg, I.C. Roberts-Thomson, R.B. Dymock, and et al. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis Gut 48 2001 206 211
73. M. Raman, I. Ahmed, P.M. Gillevet, and et al. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease Clin. Gastroenterol. Hepatol. 11 2013 868 875
74. M. Mouzaki, E.M. Comelli, B.M. Arendt, and et al. Intestinal microbiota in patients with nonalcoholic fatty liver disease Hepatology 58 2013 120 127
75. L. Miele, V. Valenza, T.G. La, and et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease Hepatology 49 2009 1877 1887
76. T. Sharifnia, J. Antoun, T.G. Verriere, and et al. Hepatic TLR4 signaling in obese NAFLD Am. J. Physiol. Gastrointest. Liver Physiol. 2015 ajpgi
77. V.W. Wong, C.H. Tse, T.T. Lam, and et al. Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis - a longitudinal study PLoS One 8 2013 e62885
78. M.S. De, C. Rychlicki, L. Agostinelli, and et al. Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice Hepatology 59 2014 1738 1749
79. V. Tremaroli, and F. Backhed Functional interactions between the gut microbiota and host metabolism Nature 489 2012 242 249
80. Y.Y. Ma, L. Li, C.H. Yu, and et al. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis World J. Gastroenterol. 19 2013 6911 6918
81. N.J. Kellow, M.T. Coughlan, and C.M. Reid Metabolic benefits of dietary prebiotics in human subjects: a systematic review of randomised controlled trials Br. J. Nutr. 111 2014 1147 1161
82. R.R. Mummadi, K.S. Kasturi, S. Chennareddygari, and et al. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis Clin. Gastroenterol. Hepatol. 6 2008 1396 1402
83. I.J. Perry, S.G. Wannamethee, and A.G. Shaper Prospective study of serum gamma-glutamyltransferase and risk of NIDDM Diabetes Care 21 1998 732 737
84. F.G. Toledo, A.D. Sniderman, and D.E. Kelley Influence of hepatic steatosis (fatty liver) on severity and composition of dyslipidemia in type 2 diabetes Diabetes Care 29 2006 1845 1850
85. H. Wang, A.D. Quiroga, and R. Lehner Analysis of lipid droplets in hepatocytes Methods Cell Biol. 116 2013 107 127
86. R. Meshkani, and K. Adeli Hepatic insulin resistance, metabolic syndrome and cardiovascular disease Clin. Biochem. 42 2009 1331 1346
87. J.P. Despres Intra-abdominal obesity: an untreated risk factor for Type 2 diabetes and cardiovascular disease J. Endocrinol. Investig. 29 2006 77 82
88. K.H. Liu, Y.L. Chan, W.B. Chan, and et al. Mesenteric fat thickness is an independent determinant of metabolic syndrome and identifies subjects with increased carotid intima-media thickness Diabetes Care 29 2006 379 384
89. G. Musso, M. Cassader, and R. Gambino Cholesterol-lowering therapy for the treatment of nonalcoholic fatty liver disease: an update Curr. Opin. Lipidol. 22 2011 489 496
90. H.M. Colhoun, D.J. Betteridge, P.N. Durrington, and et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Lancet 364 2004 685 696
91. C.P. Cannon, M.A. Blazing, R.P. Giugliano, and et al. Ezetimibe added to statin therapy after acute coronary syndromes N. Engl. J. Med. 372 2015 2387 2397
92. R. Shibata, K. Sato, D.R. Pimentel, and et al. Adiponectin protects against myocardial ischemia-reperfusion injury through Nat. Med. 11 2005 1096 1103
93. S. Lim, B.K. Koo, S.W. Cho, and et al. Association of adiponectin and resistin with cardiovascular events in Korean patients with type 2 diabetes: the Korean atherosclerosis study (KAS): a 42-month prospective study Atherosclerosis 196 2008 398 404
94. C. Pagano, G. Soardo, W. Esposito, and et al. Plasma adiponectin is decreased in nonalcoholic fatty liver disease Eur. J. Endocrinol. 152 2005 113 118
95. V.G. Giby, and T.A. Ajith Role of adipokines and peroxisome proliferator-activated receptors in nonalcoholic fatty liver disease World J. Hepatol. 6 2014 570 579
96. V. Braunersreuther, G.L. Viviani, F. Mach, and et al. Role of cytokines and chemokines in non-alcoholic fatty liver disease World J. Gastroenterol. 18 2012 727 735
97. A.C. Tuyama, and C.Y. Chang Non-alcoholic fatty liver disease J. Diabetes 4 2012 266 280
98. M.C. Alessi, D. Bastelica, A. Mavri, and et al. Plasma PAI-1 levels are more strongly related to liver steatosis than to adipose tissue accumulation Arterioscler. Thromb. Vasc. Biol. 23 2003 1262 1268
99. W. Long, J.Z. Hui, Z. Fan, and et al. The effect of recombinant adeno-associated virus-adiponectin (rAAV2/1-Acrp30) on glycolipid dysmetabolism and liver morphology in diabetic rats Gen. Comp. Endocrinol. 206 2014 1 7
100. X.C. Wang, X.R. Zhan, X.Y. Li, and et al. Identification and validation co-differentially expressed genes with NAFLD and insulin resistance Endocrine 48 2015 143 151
101. H. Tilg, and A. Moschen Update on nonalcoholic fatty liver disease: genes involved in nonalcoholic fatty liver disease and associated inflammation Curr. Opin. Clin. Nutr. Metab. Care 13 2010 391 396